Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against GW Pharmaceuticals plc

NEW YORK, Jan. 22, 2016 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a securities class action has been filed in the United States District Court for the Southern District of New York on behalf of a class (the "Class") consisting of all persons or entities who purchased GW Pharmaceuticals plc ("GW Pharmaceuticals" or the "Company") (GWPH) American Depository Receipts ("ADRs") between December 4, 2014 and January 8, 2016 (the "Class Period").  The complaint charges GW Pharmaceuticals and certain of its officers with violations of the Securities Exchange Act of 1934. 

Bernstein Liebhard LLP.

GW Pharmaceuticals is a biopharmaceutical company that, along with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines.

The complaint charges GW Pharmaceuticals and certain of its officers with violations of the federal securities laws.  Specifically, the complaint alleges that throughout the Class Period, Defendants failed to disclose that: (1) the Company lacked...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.